Insider Transactions Reported by 31 Insiders of CRESCENT BIOPHARMA, INC.

Symbol
CBIO on Nasdaq
Location
Waltham, MA

Insiders trading volume in the past year

CRESCENT BIOPHARMA, INC. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Fairmount Funds Management LLC Director, 10%+ Owner $60,557,872 +$19,999,999 +49% 04 Dec 2025
Scott D. Sandell 10%+ Owner $5,279,783 25 Jan 2023
Joshua T. Brumm Chief Executive Officer, Director $4,878,636 15 Dec 2025
Jonathan McNeill President and COO $2,408,381 15 Dec 2025
Siren, L.L.C. 10%+ Owner $2,294,139 25 Jul 2024
Rachel K. King Director $1,545,582 01 May 2024
Invus Public Equities, L.P. 10%+ Owner $1,211,077 07 Aug 2024
Christopher Grant Doughty Chief Business Officer $937,885 15 Dec 2025
John L. Magnani SVP of Research, CSO $875,378 11 Nov 2022
Chinmaya Rath SVP and Chief Business Officer $380,380 12 Jan 2024
Jan Pinkas Chief Scientific Officer $339,405 15 Dec 2025
Bruce S. Johnson SVP & Chief Commercial Officer $327,993 12 Jan 2024
Ellie Eunkyung Im Chief Medical Officer $321,173 15 Dec 2025
Daniel M. Junius Director $295,377 01 May 2024
Richard William Scalzo Chief Financial Officer $292,883 15 Dec 2025
Barbara Harlin Bispham General Counsel and Corporate Secretary. $277,803 15 Dec 2025
Ryan Lynch Treasurer, Senior Vice President of Finance and Chief Accounting Officer. $186,660 15 Dec 2025
Edwin Rock Chief Medical Officer $181,736 20 Jun 2024
Patricia S. Andrews Director $138,315 01 May 2024
Mark Alan Goldberg Director $108,975 01 May 2024
Scott Koenig Director $86,730 01 May 2024
Armand Girard SVP, Chief Business Officer $68,820 11 Nov 2022
Brian M. Hahn SVP Finance, CFO $17,498 18 Jun 2024
Jonathan Violin Director $14,598 23 Jun 2025
BVF PARTNERS L P/IL 10%+ Owner $13,100 13 Jun 2025
Susan Moran Director 23 Jun 2025
Timothy R. Pearson Director 01 May 2024
Harout Semerjian Chief Executive Officer, Director 12 Jan 2024
David Charles Lubner Director 23 Jun 2025
Scott Thomas Jackson Director 01 May 2024
Alexandra Balcom Director 23 Jun 2025

Recent Insider Transactions by Companies or Individuals for CRESCENT BIOPHARMA, INC.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Jan Pinkas GLYC Ordinary Shares Award 22,507 22,507 15 Dec 2025 Direct
Jan Pinkas GLYC Stock Option (Right to Buy) Award 70,025 70,025 15 Dec 2025 Direct
Christopher Grant Doughty GLYC Ordinary Shares Award 57.5% 22,714 62,194 15 Dec 2025 Direct
Christopher Grant Doughty GLYC Stock Option (Right to Buy) Award 58,855 58,855 15 Dec 2025 Direct
Joshua T. Brumm GLYC Ordinary Shares Award 20.5% 55,117 323,517 15 Dec 2025 Direct
Joshua T. Brumm GLYC Stock Option (Right to Buy) Award 180,467 180,467 15 Dec 2025 Direct
Richard William Scalzo GLYC Ordinary Shares Award 19,422 19,422 15 Dec 2025 Direct
Richard William Scalzo GLYC Stock Option (Right to Buy) Award 57,688 57,688 15 Dec 2025 Direct
Jonathan McNeill GLYC Ordinary Shares Award 19% 25,507 159,707 15 Dec 2025 Direct
Jonathan McNeill GLYC Stock Option (Right to Buy) Award 78,029 78,029 15 Dec 2025 Direct
Ellie Eunkyung Im GLYC Ordinary Shares Award 21,298 21,298 15 Dec 2025 Direct
Ellie Eunkyung Im GLYC Stock Option (Right to Buy) Award 65,190 65,190 15 Dec 2025 Direct
Ryan Lynch GLYC Ordinary Shares Award 12,378 12,378 15 Dec 2025 Direct
Ryan Lynch GLYC Stock Option (Right to Buy) Award 33,512 33,512 15 Dec 2025 Direct
Barbara Harlin Bispham GLYC Ordinary Shares Award 18,422 18,422 15 Dec 2025 Direct
Barbara Harlin Bispham GLYC Stock Option (Right to Buy) Award 72,185 72,185 15 Dec 2025 Direct
Jonathan McNeill GLYC Stock Option (Right to Buy) Award 172,836 172,836 08 Dec 2025 Direct
Joshua T. Brumm GLYC Stock Option (Right to Buy) Award 345,672 345,672 08 Dec 2025 Direct
Fairmount Funds Management LLC GLYC Ordinary Shares Purchase 98% $18,237,600 $13.41 1,360,000 2,747,866 04 Dec 2025 By Fairmount Healthcare Fund II L.P.
Fairmount Funds Management LLC GLYC Pre-Funded Warrant (Right to Buy) Purchase 8.03% 131,434 1,768,140 04 Dec 2025 By Fairmount Healthcare Fund II L.P.
Jan Pinkas GLYC Stock Option (Right to Buy) Award 142,474 142,474 16 Jul 2025 Direct
Susan Moran GLYC Stock Option (Right to Buy) Award 9,023 9,023 23 Jun 2025 Direct
Fairmount Funds Management LLC GLYC Stock Option (Right to Buy) Award 9,023 9,023 23 Jun 2025 By: Peter Harwin
Jonathan Violin GLYC Stock Option (Right to Buy) Award 9,023 9,023 23 Jun 2025 Direct
Alexandra Balcom GLYC Stock Option (Right to Buy) Award 9,023 9,023 23 Jun 2025 Direct
David Charles Lubner GLYC Stock Option (Right to Buy) Award 9,023 9,023 23 Jun 2025 Direct
Bvf Partners L P/Il GLYC Common Stock Other 1,270,004 707,116 13 Jun 2025 Direct
Bvf Partners L P/Il GLYC Pre-Funded Warrants to Purchase Common Stock Other 587,557 304,098 13 Jun 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.